Unknown

Dataset Information

0

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.


ABSTRACT:

Aim

To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).

Methods

Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models.

Results

Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL at DAA treatment initiation, 41% were cirrhotic, and 68% were HCV treatment-experienced. Virological treatment failures occurred in 22 patients and were mainly relapses (17, 77%) then undefined failures (3, 14%) and non-responses (2, 9%). Mean treatment duration was 16 wk overall. Post-treatment NS3, NS5A or NS5B RAS were detected in 10/14 patients with samples available for sequencing analysis. After adjustment for age, sex, ribavirin use, HCV genotype and treatment duration, low platelet count was the only factor significantly associated with a higher risk of failure (OR: 6.5; 95%CI: 1.8-22.6).

Conclusion

Only 3.9% HIV-HCV coinfected patients failed DAA regimens and RAS were found in 70% of those failing. Low platelet count was independently associated with virological failure.

SUBMITTER: Salmon D 

PROVIDER: S-EPMC6280155 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Aim</h4>To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).<h4>Methods</h4>Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-  ...[more]

Similar Datasets

| S-EPMC6750843 | biostudies-literature
| S-EPMC4267502 | biostudies-literature
| S-EPMC4548465 | biostudies-literature
| S-EPMC3629002 | biostudies-other
| S-EPMC2966433 | biostudies-literature
| S-EPMC6408225 | biostudies-literature
| S-EPMC7766690 | biostudies-literature
| S-EPMC6715635 | biostudies-literature
| S-EPMC8402799 | biostudies-literature
| S-EPMC4643888 | biostudies-literature